<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2696-130X</journal-id>
<journal-title><![CDATA[Revista mexicana de angiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. angiol.]]></abbrev-journal-title>
<issn>2696-130X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Angiología, Cirugía Vascular y Endovascular A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2696-130X2025000100003</article-id>
<article-id pub-id-type="doi">10.24875/rma.24000069</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efecto del cilostazol en la maduración de fístulas arteriovenosas en pacientes con enfermedad renal crónica]]></article-title>
<article-title xml:lang="en"><![CDATA[Effect of cilostazol on the maturation of arteriovenous fistulas in patients with chronic kidney disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bernal-González]]></surname>
<given-names><![CDATA[Carlos J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Taylor]]></surname>
<given-names><![CDATA[Jaime G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mojica-Rodríguez]]></surname>
<given-names><![CDATA[Claudia E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Gutiérrez]]></surname>
<given-names><![CDATA[Ma. Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cervantes-Domínguez]]></surname>
<given-names><![CDATA[César U.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ledezma-Verdeja]]></surname>
<given-names><![CDATA[Hilda P.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Heredia]]></surname>
<given-names><![CDATA[Tonatiuh]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Civil de Guadalajara Fray Antonio Alcalde Departamento de Cirugía de Tórax y Cardiovascular ]]></institution>
<addr-line><![CDATA[Guadalajara ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Guadalajara Departamento de Ciencias Biomédicas ]]></institution>
<addr-line><![CDATA[Guadalajara ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>53</volume>
<numero>1</numero>
<fpage>16</fpage>
<lpage>20</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2696-130X2025000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2696-130X2025000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2696-130X2025000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: El cilostazol tiene efectos sobre el endotelio vascular que podrían favorecer la maduración de la fístula arteriovenosa al inhibir la agregación plaquetaria, producir vasodilatación y reducir la proliferación vascular.  Objetivo: Evaluar la relación entre el uso de cilostazol y la maduración de fístulas arteriovenosas.  Método: Estudio de cohorte retrospectivo con 62 pacientes sometidos a confección de fístula arteriovenosa para hemodiálisis. Se formaron dos grupos: 30 pacientes que recibieron cilostazol y 32 que no lo recibieron. La maduración se consideró exitosa según criterios ultrasonográficos.  Resultados: En el grupo con cilostazol, el 86.6% (n = 26) logró una maduración exitosa, frente al 78.1% (n = 25) del grupo sin el fármaco. El riesgo relativo [(RR) de 1.109 (86.7 vs. 78.1%; IC95%: 0.289-4.260; p = 0.584], sin diferencia estadísticamente significativa.  Conclusión: En nuestro estudio, el cilostazol no mostró un efecto significativo en la maduración de fístulas arteriovenosas y no hubo evidencia suficiente para recomendar o descartar su uso como coadyuvante en este proceso.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Cilostazol has effects on the vascular endothelium that could promote arteriovenous fistula maturation by inhibiting platelet aggregation, inducing vasodilation, and reducing vascular proliferation.  Objective: To evaluate the relationship between cilostazol use and arteriovenous fistula maturation.  Method: A retrospective cohort study involving 62 patients who underwent native arteriovenous fistula creation for hemodialysis. Two groups were formed: 30 patients who received cilostazol and 32 who did not. Maturation was considered successful based on ultrasonographic criteria.  Results: In the cilostazol group, 86.6% (n = 26) achieved successful maturation, compared to 78.1% (n = 25) in the non-cilostazol group. The relative risk [(RR) was 1.109 (86.7 vs. 78.1%; 95% CI: 0.289-4.260; p = 0.584], showing no statistically significant difference.  Conclusion: In our study, cilostazol did not demonstrate a significant effect on arteriovenous fistula maturation, and there was insufficient evidence to recommend or rule out its use as an adjuvant in this process.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad renal crónica]]></kwd>
<kwd lng="es"><![CDATA[Fístula arteriovenosa]]></kwd>
<kwd lng="es"><![CDATA[Cilostazol]]></kwd>
<kwd lng="en"><![CDATA[Chronic kidney disease]]></kwd>
<kwd lng="en"><![CDATA[Arteriovenous fistula]]></kwd>
<kwd lng="en"><![CDATA[Cilostazol]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kovesdy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of chronic kidney disease:an update 2022]]></article-title>
<source><![CDATA[Kidney Int Suppl]]></source>
<year>2022</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-11</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Estadística y Geografía (INEGI)</collab>
<source><![CDATA[Estadísticas de defunciones registradas (EDR)]]></source>
<year>2023</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[INEGI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular access for hemodialysis patients:new data should guide decision making]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2019</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>954-61</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lok]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shenoy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yevzlin]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Abreo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[KDOQI Clinical Practice Guideline for Vascular Access:2019 Update]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2020</year>
<volume>75</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>S1-S164</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic factors for arteriovenous fistula maturation]]></article-title>
<source><![CDATA[Ann Vasc Surg]]></source>
<year>2018</year>
<volume>49</volume>
<page-range>273-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Berceli]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Scali]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Allon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arteriovenous fistula maturation, functional patency, and intervention rates]]></article-title>
<source><![CDATA[JAMA Surg]]></source>
<year>2021</year>
<volume>156</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1111-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wongmahisorn]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maturation of arteriovenous fistulas in patients with and without preexisting hemodialysis catheters]]></article-title>
<source><![CDATA[Ann Med Surg (Lond)]]></source>
<year>2019</year>
<volume>48</volume>
<page-range>11-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ageno]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Amato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Favaretto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Porfidia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Visonà]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cilostazol for peripheral arterial disease - A position paper from the Italian Society for Angiology and Vascular Medicine]]></article-title>
<source><![CDATA[Vasa]]></source>
<year>2024</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109-19</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kherallah]]></surname>
<given-names><![CDATA[RY]]></given-names>
</name>
<name>
<surname><![CDATA[Khawaja]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Angiolillo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Birnbaum]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cilostazol:a review of basic mechanisms and clinical uses]]></article-title>
<source><![CDATA[Cardiovasc Drugs Ther]]></source>
<year>2022</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>777-92</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>IBM Corp</collab>
<source><![CDATA[IBM SPSS Statistics for Windows, version 26.0]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Armonk, NY ]]></publisher-loc>
<publisher-name><![CDATA[IBM Corp]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Kasper]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Seiwert]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Comerota]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lurie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cilostazol may improve maturation rates and durability of vascular access for hemodialysis]]></article-title>
<source><![CDATA[Vasc Endovascular Surg]]></source>
<year>2017</year>
<volume>51</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>120-4</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Ham]]></surname>
<given-names><![CDATA[YR]]></given-names>
</name>
<name>
<surname><![CDATA[Na]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of cilostazol on arteriovenous fistula in hemodialysis patients]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year>2021</year>
<volume>41</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>625-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ibeas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roca-Tey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vallespín]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Moñux]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martí-Monrós]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spanish Clinical Guidelines on Vascular Access for Haemodialysis]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year>2017</year>
<volume>37</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>1-191</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
